Philip G. Vanek｜GE 医疗细胞治疗发展战略总经理

Philip G. Vanek, PhD
GE 医疗生命科学事业部细胞治疗发展战略总经理
GM Cell Therapy Growth Strategy, GE Healthcare

在 GE，Phil 领导的团队专注于细胞治疗业务发展战略项目，包括投资合作 BridGE@CCRM 和 Vitruvian 系统, 以及参与并购 Biosafe 公司和英国的 Asymptote 公司。加入 GE 之前，Phil 是龙沙（Lonza）制药创新药部门的负责人，领导团队专注于在细胞、蛋白和病毒治疗生产的新技术开发。Phil 曾在 BD、Invitrogen、Life Technologies 任职, 也曾参与了在华盛顿地区的两家创业生物科技公司的业务开发和市场拓展. 

Dr. Vanek is General Manager of Cell Therapy Growth Strategy for GE Healthcare. Phil’s team built the strategy that lead to investments including BridGE@CCRM and Vitruvian Networks, as well as the acquisitions of Biosafe in Switzerland, and Asymptote LTD in the UK. Prior to joining GE, Phil was Head of Innovation for Lonza’s Pharmaceutical division, leading a group to drive new technology initiatives focused on cell, protein, and viral therapeutic manufacturing. Phil’s career also included a number of senior innovation, business and market development roles at Becton Dickinson (BD), Invitrogen, and Life Technologies, as well as two start-up biotechnology 

编辑： zhuq    来源：丁香园